In New Zealand, can a patient be eligible for empagliflozin and GLP-1 RA?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18615396
Cited by: 0

Abstract

Patients in New Zealand may be eligible for empagliflozin and GLP-1 RAs depending on individual risk profiles and specific criteria for accessing funded therapies, mainly prioritizing those with cardiovascular or renal risks.

Fields of Study & Subjects

Diabetes Treatment and Management Heart Failure Treatment and Management Pharmaceutical Economics and Policy

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
11 February 2026
Language
EN